- Product Pipeline Review - H2 2011” provides a detailed overview on the Northwest Biotherapeutics, Inc.’s research and development focus. The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industries Direct’s proprietary databases, Northwest Biotherapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Northwest Biotherapeutics, Inc. and market -specific third party sources, put together by Global Industries Direct’s team.

Scope of the Research

- Northwest Biotherapeutics, Inc. - Brief Northwest Biotherapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Northwest Biotherapeutics, Inc. human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Northwest Biotherapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Northwest Biotherapeutics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate Northwest Biotherapeutics, Inc.’s strategic position with total access to detailed data on its product pipeline.
- Assess the growth opportunities of Northwest Biotherapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Northwest Biotherapeutics, Inc.’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Northwest Biotherapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Northwest Biotherapeutics, Inc. and identify potential opportunities in those areas.

Table Of Contents

Table of Contents
Data table of Contents 2
List of Tables 4
List of Figures 5
Northwest Biotherapeutics, Inc. Snapshot 6
Northwest Biotherapeutics, Inc. Overview 6
Key Information 6
Key Facts 6
Northwest Biotherapeutics, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Northwest Biotherapeutics, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Northwest Biotherapeutics, Inc. - Pipeline Products Glance 11
Northwest Biotherapeutics, Inc. Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
Northwest Biotherapeutics, Inc.-Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
Northwest Biotherapeutics, Inc. - Drug Profiles 13
CXCR4 Antibody 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
DCVax-Head and Neck 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
DCVax-LB 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
DCVax-Liver 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
DCVax-Pancreas 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Northwest Biotherapeutics, Inc. - Pipeline Analysis 18
Northwest Biotherapeutics, Inc. - Pipeline Products by Therapeutic Class 18
Northwest Biotherapeutics, Inc. - Pipeline Products By Target 19
Northwest Biotherapeutics, Inc. - Pipeline Products by Molecule Type 20
Northwest Biotherapeutics, Inc. - Recent Pipeline Updates 21
Northwest Biotherapeutics, Inc. - Firms Statement 23
Northwest Biotherapeutics, Inc. - Operations and Subsidiaries 25
Head Office 25
Other Locations and Subsidiaries 25
Recent Developments 26
January 31, 2005: Northwest Biotherapeutics, Inc. To Initiate Phase III Clinical Trial For DCVax-Prostate For Prostate Cancer 26
January 31, 2005: Northwest Biotherapeutics, Inc. To Initiate Phase III Clinical Trial For DCVax-Prostate For Prostate Cancer 26
November 28, 2006: Northwest Biotherapeutics Receives Institutional Review Board Approval To Accrue Patients In Phase II Brain Cancer Trial 27
August 28, 2006: Northwest Biotherapeutics Updates Brain Cancer Clinical Data For DCVax-Brain 27
May 25, 2011: Northwest Biotherapeutics Further Expands Ongoing Brain Cancer Trial 28
January 24, 2011: Northwest Biotherapeutics Resuming Enrollment In 240-Patient Clinical Trial Of DCVax For Brain Cancer 28
December 23, 2008: Northwest Biotherapeutics Announces Phase I/II Clinical Trial Results Of DCVax-L In Metastatic Ovarian Cancer 29
July 23, 2003: Northwest Biotherapeutics, Inc. To Present Favorable Data On Effects Of DCVax-Prostate On Progression Of Advanced-Stage Prostate Cancer 30
May 23, 2006: Northwest Biotherapeutics Updates Brain Cancer Clinical Data Of DCVax-Brain 30
February 22, 2006: Brain Cancer Patients Living Longer And Doing Better After Personalized Vaccine Therapy 31
October 21, 2009: Long-Term Data Updates Show Further Extensions Of Survival And Delays In Recurrence In Brain Cancer Patients Who Received DCVax-Brain 32
September 21, 2011: Swedish's Ivy Brain Tumor Center Launches New Clinical Trial With DCVax To Treat Brain Cancer 33
February 20, 2008: Phase I and Phase I/II DCVax-Brain Data Continues to show Significantly Improved Survival Rates for Brain Cancer Patients 34
May 18, 2011: Northwest Biotherapeutics And Fraunhofer Partner For Clinical Trials And Compassionate Use Cases In Europe 35
February 17, 2009: Update of Long-Term Data on Brain Cancer Patients Receiving DCVax-Brain Continues to Show Striking Improvements in Delay of Disease and Survival 35
February 17, 2006: Northwest Biotherapeutics To Present New Data On CXCR4 At The Molecular Medicine Tri-Conference 36
August 15, 2006: Northwest Biotherapeutics Signs Synteract For Management Of Its DCVax-Brain Cancer Phase II Clinical Trial 36
February 13, 2007: First Patients Undergo Surgery In Northwest Biotherapeutics’ Phase II Brain Cancer Trial 37
September 11, 2008: Long-Term Phase I And Phase I/II Trial Data Continue To Show Striking Improvement In Survival Of Brain Cancer Patients Who Receive DCVax-Brain 38
July 09, 2007: Swiss “Authorization for Use” Approved for Northwest Biotherapeutics' DCVax-Brain 39
July 07, 2003: Northwest Biotherapeutics’ Initial DCVax-Direct Clinical Evaluation Being Planned At H. Lee Moffitt Cancer Center 39
July 07, 2003: Northwest Biotherapeutics’ Initial DCVax®-Direct Clinical Evaluation Being Planned At H. Lee Moffitt Cancer Center 40
March 07, 2007: Northwest Biotherapeutics Adds UCLA As A Site To Its Pivotal Phase II Brain Cancer Trial 40
October 06, 2011: Northwest Bio Announces Positive Third Quarter Clinical Trial Progress 41
October 04, 2011: Northwest Bio To Present At Second Annual Cancer Immunotherapy At New York Academy Of Medicine 42
August 04, 2011: Northwest Biotherapeutics Announces Further Expansion Of Clincal Sites In Ongoing Brain Cancer Trial 43
August 03, 2010: Northwest Biotherapeutics Announces Long-Term Follow-Up Data Of DCVax-Brain Immune Therapy In Brain Cancer Patients 44
May 03, 2011: Northwest Biotherapeutics Announces Ongoing Recruitment For Brain Cancer Trial In US 45
January 03, 2008: Penn's Center For Research On Early Detection And Cure Of Ovarian Cancer And Abramson Cancer Center, With Northwest Biotherapeutics Conduct Ovarian Cancer Clinical Trial With DCVax-L 45
June 01, 2005: Northwest Biotherapeutics, Inc. Brain Cancer Treatment To Undergo Broader Testing Based On Encouraging Phase I Clinical Trial 46
Financial Deals Landscape 48
Northwest Biotherapeutics, Inc., Merger and Acquisition Deal Summary 48
Northwest Biotherapeutics, Inc., Pharmaceuticals and Healthcare, Merger and Acquisition Deal Details 49
Equity Offering 49
Northwest Biotherapeutics Announces Private Placement Of US$ 4.6 Mln 49
Northwest Biotherapeutics Completes Private Placement Of US$ 2.65 Mln 50
Northwest Biotherapeutics Completes Private Placement Of US$ 0.73 Mln 52
Northwest Biotherapeutics Completes Private Placement Of US$ 0.7 Mln 54
Northwest Biotherapeutics Completes Private Placement Of US$ 29.8 Mln 56
Northwest Biotherapeutics Completes Private Placement Of US$ 30 Mln 58
Northwest Biotherapeutics Completes Private Placement Of US$ 5.53 Mln 60
Northwest Biotherapeutics Completes Private Placement Of US$ 1.3 Mln 62
Northwest Biotherapeutics Completes Initial Public Offering US$ 20 Mln 64
Debt Offering 66
Northwest Biotherapeutics Completes Private Placement Of Convertible Notes For US$ 3 Mln 66
Northwest Biotherapeutics Completes Private Placement Of Notes For US$ 0.4 Mln 67
Northwest Biotherapeutics Completes Private Placement Of 12% Notes For US$ 0.5 Mln 68
Northwest Biotherapeutics Completes Private Placement Of 12% Note For US$ 1 Mln 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 71
Contact Us 71
Disclaimer 71

List of Tables

Northwest Biotherapeutics, Inc. - Pipeline by Therapy Area and Indication, H2 2011 8
Northwest Biotherapeutics, Inc. - Pipeline by Stage of Development, H2 2011 9
Northwest Biotherapeutics, Inc. - Monotherapy Products in Pipeline, H2 2011 10
Northwest Biotherapeutics, Inc. - Phase I, H2 2011 11
Northwest Biotherapeutics, Inc. - Pipeline By Therapeutic Class, H2 2011 18
Northwest Biotherapeutics, Inc. - Pipeline By Target, H2 2011 19
Northwest Biotherapeutics, Inc. - Pipeline By Molecule Type, H2 2011 20
Northwest Biotherapeutics, Inc. - Recent Pipeline Updates, H2 2011 21
Northwest Biotherapeutics, Inc., Subsidiaries 25
Northwest Biotherapeutics, Inc., Merger and Acquisition Deal Summary 48
Northwest Biotherapeutics Announces Private Placement Of US$ 4.6 Mln 49
Northwest Biotherapeutics Completes Private Placement Of US$ 2.65 Mln 50
Northwest Biotherapeutics Completes Private Placement Of US$ 0.73 Mln 52
Northwest Biotherapeutics Completes Private Placement Of US$ 0.7 Mln 54
Northwest Biotherapeutics Completes Private Placement Of US$ 29.8 Mln 56
Northwest Biotherapeutics Completes Private Placement Of US$ 30 Mln 58
Northwest Biotherapeutics Completes Private Placement Of US$ 5.53 Mln 60
Northwest Biotherapeutics Completes Private Placement Of US$ 1.3 Mln 62
Northwest Biotherapeutics Completes Initial Public Offering US$ 20 Mln 64
Northwest Biotherapeutics Completes Private Placement Of Convertible Notes For US$ 3 Mln 66
Northwest Biotherapeutics Completes Private Placement Of Notes For US$ 0.4 Mln 67
Northwest Biotherapeutics Completes Private Placement Of 12% Notes For US$ 0.5 Mln 68
Northwest Biotherapeutics Completes Private Placement Of 12% Note For US$ 1 Mln 69

List of Figures

Northwest Biotherapeutics, Inc. - Pipeline by Therapy Area and Indication, H2 2011 8
Northwest Biotherapeutics, Inc. - Pipeline by Stage of Development, H2 2011 9
Northwest Biotherapeutics, Inc. - Monotherapy Products in Pipeline, H2 2011 10
Northwest Biotherapeutics, Inc. - Pipeline By Therapeutic Class, H2 2011 18
Northwest Biotherapeutics, Inc. - Pipeline By Molecule Type, H2 2011 20

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Arno Therapeutics, Inc. - Product Pipeline Review - 2014

Arno Therapeutics, Inc. - Product Pipeline Review - 2014

  • $ 1 500
  • Company report
  • July 2014
  • by Global Markets Direct

Arno Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, ‘Arno Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Arno Therapeutics, Inc.'s ...

VistaGen Therapeutics, Inc. - Product Pipeline Review - 2014

VistaGen Therapeutics, Inc. - Product Pipeline Review - 2014

  • $ 1 500
  • Company report
  • July 2014
  • by Global Markets Direct

VistaGen Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, ‘VistaGen Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the VistaGen Therapeutics ...

Esperion Therapeutics, Inc. - Product Pipeline Review - 2014

Esperion Therapeutics, Inc. - Product Pipeline Review - 2014

  • $ 1 500
  • Company report
  • July 2014
  • by Global Markets Direct

Esperion Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, ‘Esperion Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Esperion Therapeutics, ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.